NSCLC cells with BRAF mutations where shown to be more sensitive to MEK inhibitors than NSCLC with mutations in EGFR, KRAS, or the chimeric fusion between ALK and ROS [101]. Here, MAP2K7 is linked to non-small cell lung carcinoma.